

Publikations- und Vortragsverzeichnis

Ingo Rustenbeck

I Publikationen in referierten Zeitschriften

- 1 Lenzen S, Rustenbeck I und Panten U (1984) Transamination of 3-phenylpyruvate in pancreatic B-cell mitochondria. J Biol Chem 259: 2043-2046
- 2 Lenzen S, Schmidt W, Rustenbeck I und Panten U (1986) 2-Ketoglutarate generation in pancreatic B-cell mitochondria regulates insulin secretory action of amino acids. Biosci Rep 6: 163-169
- 3 Rustenbeck I und Lenzen S (1989) Effects of lysophosphatidylcholine and arachidonic acid on the regulation of intracellular Ca^{2+} transport. Naunyn-Schmiedeberg's Arch Pharmacol 339: 37-41
- 4 Rustenbeck I, Trümner A und Lenzen S (1989) Densitometric quantification of major and minor phospholipids from subcellular fractions of insulin secreting cells. J Planar Chromatogr 2: 207-210
- 5 Lenzen S, Görlich JK und Rustenbeck I (1989) Regulation of transmembrane ion transport by reaction products of phospholipase A_2 . I. Effects of lysophospholipids on mitochondrial Ca^{2+} transport. Biochim Biophys Acta 982: 140-146
- 6 Rustenbeck I und Lenzen S (1989) Regulation of transmembrane ion transport by reaction products of phospholipase A_2 . II. Effects of arachidonic acid and other fatty acids on mitochondrial Ca^{2+} transport. Biochim Biophys Acta 982: 147-155
- 7 Rustenbeck I und Lenzen S (1989) Densitometric quantification of minor phospholipids via improvement of the scanning mode for cupric sulfate staining. J Planar Chromatogr 2: 470-472
- 8 Rustenbeck I und Lenzen S (1990) Quantitation of hexadecylphosphocholine by high-performance thin-layer chromatography with densitometry. J Chromatogr 525: 85-91
- 9 Lenzen S und Rustenbeck I (1991) Effects of IP_3 , spermine, and Mg^{2+} on regulation of Ca^{2+} transport by endoplasmic reticulum and mitochondria in permeabilized pancreatic islets. Diabetes 40: 323-326
- 10 Rustenbeck I, Eibl HJ und Lenzen S (1991) Structural requirements of lysophospholipid-regulated mitochondrial Ca^{2+} transport. Biochim Biophys Acta 1069: 99-109

- 11 Rustenbeck I und Lenzen S (1992) Effect of lysophospholipids, arachidonic acid and other fatty acids on regulation of Ca^{2+} transport in permeabilized pancreatic islets. *Cell Calcium* 13: 193-202
- 12 Lenzen S, Münster W und Rustenbeck I (1992) Dual effect of spermine on mitochondrial Ca^{2+} transport. *Biochem J* 286: 597-602
- 13 Rustenbeck I, Eggers G, Münster W und Lenzen S (1993) The effect of spermine on mitochondrial matrix calcium in relation to its enhancement of mitochondrial calcium uptake. *Biochem Biophys Res Commun* 194: 1261-1268
- 14 Rustenbeck I, Matthies A und Lenzen S (1994) Lipid composition of glucose-stimulated pancreatic islets and insulin secreting tumor cells. *Lipids* 29: 685-692
- 15 Rustenbeck I, Löptien D und Lenzen S (1995) Degradation of dansyl polyamines on high-performance thin-layer chromatographic plates. *J Chromatogr B*, 667: 185-187
- 16 Rustenbeck I, Kowalewski R, Herrmann C, Dickel C, Ratzka P und Hasselblatt A (1995) Effects of imidazoline compounds on cytoplasmic Ca^{2+} concentration and ATP-sensitive K^{+} channels in pancreatic B-cells. *Exp Clin Endocrinol Diabetes* 103 (suppl 2): 42-45
- 17 Rustenbeck I und Lenzen S (1996) A plug-in minielectrode for measurements in stirred photometric cuvettes. *J Biochem Biophys Meth* 31: 105-112
- 18 Rustenbeck I, Reiter H und Lenzen S (1996) Dissociation between polyamine effects on mitochondrial Ca^{2+} uptake and on mitochondrial permeability transition by elongation of the polyamine methylene backbone. *Biochem Mol Biol Int* 38: 1003-1011
- 19 Rustenbeck I, Münster W und Lenzen S (1996) Relation between accumulation of phospholipase A_2 reaction products and Ca^{2+} release in isolated liver mitochondria. *Biochim Biophys Acta* 1304: 129-138
- 20 Rustenbeck I, Herrmann C und Grimmsmann T (1997) Energetic requirement of insulin secretion distal to Ca^{2+} influx. *Diabetes* 46: 1305-1311
- 21 Rustenbeck I, Herrmann C, Ratzka P und Hasselblatt A (1997) Imidazoline/guanidinium binding sites and their relation to inhibition of K_{ATP} channels in pancreatic B-cells. *Naunyn-Schmiedeberg's Arch Pharmacol* 356: 410-417
- 22 Grimmsmann T und Rustenbeck I (1998) Effects of diazoxide on mitochondria in intact pancreatic B-cells and isolated liver mitochondria. *Br J Pharmacol* 123: 781-788

- 23 Rustenbeck I, Eggers G, Münster W, Reiter H und Lenzen S (1998) Polyamine modulation of mitochondrial calcium transport. I. Stimulatory and inhibitory effects of aliphatic polyamines, aminoglucosides and other polyamine analogues on mitochondrial calcium uptake. *Biochem Pharmacol* 56: 987-995
- 24 Rustenbeck I, Löptien D, Fricke K, Lenzen S und Reiter H (1998) Polyamine modulation of mitochondrial calcium transport. II. Inhibition of the mitochondrial permeability transition by aliphatic polyamines but not aminoglucosides. *Biochem Pharmacol* 56: 997-985
- 25 Rustenbeck I, Köpp M, Polzin C und Hasselblatt A (1998) No evidence for PKC activation in stimulation of insulin secretion by phentolamine. *Naunyn-Schmiedeberg's Arch Pharmacol* 358: 390-393
- 26 Krautheim A, Rustenbeck I und Steinfelder HJ (1999) Phosphatase inhibitors induce defective hormone secretion in insulin-secreting cells and entry into apoptosis. *Exp Clin Endocrinol Diabetes* 107: 29-34
- 27 Rustenbeck I, Leupolt L, Kowalewski R, Hasselblatt A (1999) Heterogeneous characteristics of imidazoline-induced insulin secretion. *Naunyn-Schmiedeberg's Arch Pharmacol* 359: 235-242
- 28 Rustenbeck I, Dickel C, Herrmann C und Grimmsmann T (1999) Mitochondria present in excised patches from pancreatic B-cells may form microcompartments with ATP-dependent potassium channels, *Biosci Rep* 19: 89-98
- 29 Rustenbeck I, Köpp M, Ratzka P, Leupolt L und Hasselblatt A: Imidazolines and the pancreatic B-cell: actions and binding sites. In: *Imidazoline Receptors and Their Endogenous Ligands*, *Annals NY Acad Sci*, Vol. 881 (M Göthert, GJ Molderings, D. Reis, Eds.), pp. 229-240, New York, 1999
- 30 Zünkler BJ, Kühne S, Rustenbeck I, Ott T und Hildebrandt AG (2000) Disopyramide block of K_{ATP} channel is mediated by the pore-forming subunit. *Life Sci* 66: 245-252
- 31 Zünkler BJ, Kühne S, Rustenbeck I und Ott T (2000) Mechanism of terfenadine block of ATP-sensitive K^+ -channels. *Br J Pharmacol* 130: 1571-1574
- 32 Hirsch K, Ziemann C, Rustenbeck I, Kahl GF (2001) Inhibitors of mdrl-dependent transport activity delay accumulation of the mdrl substrate rhodamine 123 in primary rat hepatocyte cultures. *Toxicology* 167: 47-57
- 33 Rustenbeck I, Winkler M und Jörns A (2001) Desensitization of insulin secretory response to imidazolines, tolbutamide and quinine. I. Secretory and morphological studies. *Biochem Pharmacol* 62: 1685-1694

- 34 Rustenbeck I, Dickel C und Grimmsmann T (2001) Desensitization of insulin secretory response to imidazolines, tolbutamide and quinine. II. Electrophysiological and fluorimetric studies. *Biochem Pharmacol* 62: 1695-1703
- 35 Ahmad R, Ahmad I, Rustenbeck I, Lenzen S und Duddeck H (2002) *N*-arylsulfonyl-benzimidazolones as potential hypoglycemic agents. *Z Naturforsch* 57b: 349-354
- 36 Rustenbeck I (2002) Commentary: Desensitization of insulin secretion. *Biochem Pharmacol* 63: 1921-1935
- 37 Grosse Lackmann T, Zünkler BJ und Rustenbeck I (2003), Specificity of non-adrenergic imidazoline binding sites in insulin-secreting cells and relation to the block of ATP-sensitive K⁺ channels. *Annals NY Acad Sci* 1009: 371-377
- 38 Remizov O, Jakubov R, Düfer M, Krippeit-Drews P, Drews G, Waring M, Brabant G, Wienbergen A, Rustenbeck I und Schöfl C (2003) Palmitate-induced Ca²⁺ signalling in pancreatic beta-cells. *Mol Cell Endocrinol* 212: 1-9
- 39 Rustenbeck I, Krautheim A und Steinfelder HJ (2004) Beta-cell toxicity of ATP-sensitive K⁺ channel-blocking insulin secretagogues. *Biochem Pharmacol* 67: 1733-1741
- 40 Rustenbeck I, Wienbergen A, Bleck C und Jörns A (2004) Desensitization of insulin secretion by depolarizing insulin secretagogues. *Diabetes* 53 (Suppl. 3):S140-S150
- 41 Bleck C, Wienbergen A und Rustenbeck I (2004) Glucose dependence of imidazoline-induced insulin secretion: Different characteristics of two ATP-sensitive K⁺ channel-blocking compounds. *Diabetes* 53 (Suppl. 3):S135-S139
- 42 Bleck C, Wienbergen A und Rustenbeck I (2005) Essential role of the imidazoline moiety for the insulinotropic effect but not the K_{ATP} channel blocking effect of imidazolines. *Diabetologia* 48: 2567-2575
- 43 Zünkler BJ, Claaßen S, Wos-Maganga M, Rustenbeck I und Holzgrabe U (2006) Effect of fluoroquinolones on HERG channels and on pancreatic β-cell ATP-sensitive K⁺ channels. *Toxicology* 228: 239-248
- 44 Wienbergen A, Bleck C, Grosse Lackmann T und Rustenbeck I (2007) Antagonism of the insulinotropic action of first generation imidazolines by openers of K_{ATP} channels. *Biochem Pharmacol* 73:94-102
- 45 Panten U und Rustenbeck I (2008) Fuel-induced amplification of insulin secretion in mouse pancreatic islets exposed to a high sulfonylurea concentration: role of the NADPH/NADP ratio. *Diabetologia* 51:101-109

- 46 Ghaly A, Kriete C, Shahin S, Pflöger A, Zünkler BJ, Holzgrabe U und Rustenbeck I (2009) The insulinotropic effect of fluoroquinolones. *Biochem Pharmacol* 77:1040-1052.
- 47 Willenborg M, Panten U und Rustenbeck I (2009) Triggering and amplification of insulin secretion by dimethyl- α -ketoglutarate, a membrane-permeable α -ketoglutarate analogue. *Eur J Pharmacol* 607:41-46
- 48 Hatlapatka K, Willenborg M und Rustenbeck I (2009) Plasma membrane depolarization as a determinant of the first phase of insulin secretion. *Am J Physiol Endocrinol Metab* 297:E315-322
- 49 Hatlapatka K, Wienbergen A, Bleck C, Willenborg M, Jörns A und Rustenbeck I (2009), Selective enhancement of nutrient-induced insulin secretion by K_{ATP} channel-blocking imidazolines. *J Pharmacol Exp Ther.* 331:1033-1041
- 50 Willenborg M, Ghaly H, Hatlapatka K, Urban K, Panten U, Rustenbeck I (2010) The signalling role of action potential depolarization in insulin secretion. Metabolism-dependent dissociation between action potential increase and secretion increase by TEA. *Biochem Pharmacol.* 80:104-12.
- 51 Rustenbeck I, Baltrusch S, Tiedge M. (2010) Do insulinotropic glucose-lowering drugs do more harm than good? The hypersecretion hypothesis revisited. *Diabetologia.* 53:2105-11.
- 52 Willenborg M, Hatlapatka K, Ghaly H, Belz M, Urban K, Panten U, Rustenbeck I (2011) Studies of first phase insulin secretion using imposed plasma membrane depolarization. *Front Biosci (Schol Ed).* 2011;3:662-79.
- 53 K. Hatlapatka, M. Matz, Kirstin Schumacher, K. Baumann, and I. Rustenbeck (2011) Bidirectional insulin granule turnover in the submembrane space during K^+ depolarization-induced secretion. *Traffic* 12:1166-78.
- 54 Willenborg M, Belz M, Schumacher K, Paufler A, Hatlapatka K, Rustenbeck I. (2012) Ca^{2+} -dependent desensitization of insulin secretion by strong potassium depolarization. *Am J Physiol Endocrinol Metab.* 303:E223-33.
- 55 Lehner Z, Stadlbauer K, Adorjan I, Rustenbeck I, Belz M, Fenzl A, deCillia VAM, Gruber D, Bauer L, Frobel K, Brunmair B, Luger A, Fürnsinn C. (2012) Mechanisms of antihyperglycemic action of efaroxan in mice: time for reappraisal of α_{2A} -antagonists for antidiabetic treatment? *Diabetologia* 55:3071-82.
- 56 Panten U, Willenborg M, Schumacher K, Hamada A, Ghaly H, Rustenbeck I. (2013) Acute metabolic amplification of insulin secretion in mouse islets is mediated by mitochondrial export of metabolites, but not by mitochondrial energy generation. *Metabolism* 62:1375-86.

- 57 Matz M, Schumacher K, Hatlapatka K, Lorenz D, Baumann K, Rustenbeck I. (2014) Observer-independent Quantification of Insulin Granule Exocytosis and Pre-Exocytotic Mobility by TIRF Microscopy. *Microsc Microanal.* 20:206-18.
- 58 Ghaly H, Jörns A, Rustenbeck I. (2014) Effect of fluoroquinolones on mitochondrial function in pancreatic beta cells. *Eur J Pharm Sci.* 52:206-14.
- 59 Rustenbeck I, Lier-Glaubitz V, Willenborg M, Engelhardt U Jörns, A. (2014) Effect of chronic coffee consumption on weight gain and glycemia in a mouse model of type 2 diabetes. *Nutrition and Diabetes* 4:e123. doi: 10.1038/nutd.2014.19.
- 60 Belz M, Willenborg M, Görgler N, Hamada A, Schumacher K, Rustenbeck I. (2014) Insulinotropic effect of high potassium concentration beyond plasma membrane depolarization. *Am J Physiol Endocrinol Metab.* 306:E697-706.
- 61 Stadlbauer K, Lehner Z, Stamenkovic N, Rustenbeck I, Surman L, Luger A, Fürnsinn C. (2014) Dissection of mechanisms that account for imidazoline-induced lowering of blood glucose in mice. *Eur J Pharmacol.* 741:178-85.
- 62 Schumacher K, Matz M, Brüning D, Baumann K, Rustenbeck I. (2015) Relation between granule mobility, fusion frequency and stimulated insulin secretion in MIN6 cells. *Traffic* 16:493-509.
- 63 Schulze, T, Morsi M, Brüning D, Schumacher K, Rustenbeck I (2016) Different responses of mouse islets and MIN6 pseudo-islets to metabolic stimulation. A note of caution. *Endocrine*, 51:440-7.
- 64 Panten U, Früh E, Reckers K, Rustenbeck I. (2016) Acute metabolic amplification of insulin secretion in mouse islets: Role of cytosolic acetyl-CoA. *Metabolism.* 65:1225-9.
- 65 Schulze T, Morsi M, Reckers K, Brüning D, Seemann N, Panten U, Rustenbeck I. (2017) Metabolic amplification of insulin secretion is differentially desensitized by depolarization in the absence of exogenous fuels. *Metabolism.* 67:1-13.
- 66 Schulze T, Mattern K, Früh E, Hecht L, Rustenbeck I, Dietzel A. (2017) A 3D microfluidic perfusion system made from glass for multiparametric analysis of stimulus-secretion coupling in pancreatic islets. *Biomed Microdevices.* 19:47-57. doi: 10.1007/s10544-017-0186-z.
- 67 Gregor Scholz G, Xu Q, Schulze T, Heidi Boht, Kai Mattern, Jana Hartmann, Andreas Dietzel, Stephan Scherneck, Ingo Rustenbeck, Joan Daniel Prades, Sönke Fündling, Sutomo Suryo Wasisto and Andreas Waag (2017) LED-based Tomographic Imaging for Live-Cell Monitoring of Pancreatic Islets in Microfluidic Channels. *Proceedings*

II Monographien, Buchbeiträge, Übersichten

- 1 Rustenbeck I: Transaminierungsreaktionen von 3-Phenylpyruvat mit L-Glutamat und L-Glutamin in Mitochondrien von B-Zellen des Pankreas von ob/ob Mäusen. Med Diss, Göttingen, 1983
- 2 Rustenbeck I und Lenzen S: Mitochondrial Ca^{2+} transport and its interactions with endoplasmic reticulum Ca^{2+} transport in pancreatic islets. In: Frontiers in B-cell research (PR Flatt und S Lenzen, eds), pp. 213-219, Smith Gordon, London, 1994
- 3 Rustenbeck I: Polyamine und Phospholipase A_2 -Produkte als endogene Regulatoren des mitochondrialen Ca^{2+} Transports. Habilitationsschrift, Göttingen, 1996
- 4 Steinfelder HJ und Rustenbeck I (1997) Pharmakologie der inneren Sekretion: Past, Present, Future. DGPT Forum 20: 16-17
- 5 Rustenbeck I (1999) Die Stimulus-Sekretions-Kopplung in den B-Zellen des Pankreas: Von der Physiologie zur Pharmakologie. Diabetes Stoffw 8: 217-222
- 6 Panten U und Rustenbeck I: Pharmakologie des Glucosestoffwechsels: Antidiabetika, Antihypoglykämika, Antihyperglykämische Pharmakotherapie des Diabetes mellitus. In: Aktories/Förstermann/Hofmann/Starke: Allgemeine und Spezielle Pharmakologie und Toxikologie, 9., überarbeitete Auflage, Urban und Fischer 2005
- 7 Rustenbeck I: Unkonventionelle adjuvante Diabetestherapie. Med Monatschr Pharm 30: 131-137, Wiss Verlagsanstalt Stuttgart 2007
- 8 Panten U und Rustenbeck I: Pharmakologie des Glucosestoffwechsels: Antidiabetika, Antihypoglykämika, Antihyperglykämische Pharmakotherapie des Diabetes mellitus. In: Aktories/Förstermann/Hofmann/Starke: Allgemeine und Spezielle Pharmakologie und Toxikologie, 10., überarbeitete Auflage, Urban und Fischer 2009
- 9 Rustenbeck I: Pro und Contra Fixkombinationen. Med Monatschr Pharm, 32:141-146, Wiss Verlagsanstalt Stuttgart 2009
- 10 Michael Willenborg, Kathrin Hatlapatka, Michael Belz und Ingo Rustenbeck Die erste Phase der Insulinsekretion. Physiologische Mechanismen, pathophysiologische Bedeutung und therapeutische Perspektiven. In: Lebendige Wissenschaft - Spitzenforschung in der Diabetologie, IWV Lampertheim, 2010

- 11 Willenborg M, Schumacher K, Rustenbeck I: Insulin secretion of isolated islets. In: "Animal models in diabetes research", Methods in Molecular Biology vol. 933 (HG Joost, H Al-Hasani, A Schürmann, eds), pp 189 - 201, Humana Press 2012
- 12 Panten U, Joost HG und Rustenbeck I: Pharmakologie des Energiestoffwechsels - Pharmakotherapie des Diabetes mellitus und der Adipositas. In: Aktories/Förstermann/Hofmann/Starke: Allgemeine und Spezielle Pharmakologie und Toxikologie, 11., überarbeitete Auflage, Urban und Fischer 2013
- 13 Rustenbeck I und Ammon HPT: Zimt und andere pflanzliche Produkte in der Diabetestherapie. In: Diabetologie kompakt, Grundlagen und Praxis (Schatz, Helmut; Pfeiffer, Andreas F.H.; Hrsg.) 5. Aufl. Springer 2014
- 14 Rustenbeck I [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes]. Med Monatsschr Pharm. 2016 Feb;39(2):65-72; quiz 73-4. Review. German.
- 15 Rustenbeck I und Joost HG: Pharmakologie des Energiestoffwechsels - Pharmakotherapie des Diabetes mellitus und der Adipositas. In: Aktories/Förstermann/Hofmann/Starke: Allgemeine und Spezielle Pharmakologie und Toxikologie, 12., überarbeitete Auflage, Urban und Fischer 2017
- 16 Rustenbeck I: Wie wirksam ist die HbA1c-Senkung? [The relation between HbA1c and clinical outcomes in type 2 diabetes]. Med Monatsschr Pharm. 2017 Nov;40(11):489-495. Review. German.

III Vorträge etc mit publiziertem Abstract

- 1 Lenzen S, Rustenbeck I und Panten U (1983) Transaminierung in den Mitochondrien des Pankreas als Signal für die Auslösung der Insulinsekretion durch β -Phenylpyruvat. Akt Endokrin Stoffw 4: 96
- 2 Lenzen S, Rustenbeck I und Panten U (1983) Transamination of L-glutamine by pancreatic B-cell mitochondria. Hoppe-Seyler's Z Physiol Chem 364: 1251
- 3 Lenzen S, Rustenbeck I und Panten U (1984) Transamination of 3-phenylpyruvate in the mitochondria from pancreatic B-cells. Naunyn-Schmiedeberg's Arch Pharmacol 325: R59
- 4 Rustenbeck I, Görlich JK und Lenzen S (1987) Interactions between endoplasmic reticulum and mitochondria in the regulation of pancreatic B-cell calcium transport. Diabetologia 30: 576A
- 5 Rustenbeck I (1988) Regulation of B-cell Ca^{2+} transport by inositol 1,4,5-trisphosphate and lysophosphatidylinositol. Naunyn-Schmiedeberg's Arch Pharmacol 337: R83
- 6 Rustenbeck I und Lenzen S (1988) Regulation des Ca^{2+} Transports in B-Zellen des Pankreas durch Inositolphosphate und Lysophospholipide. Akt End Stoffw 9: 87

- 7 Rustenbeck I und Lenzen S (1988) Role of lysophospholipids and fatty acids as regulators of pancreatic B-cell calcium transport. *Diabetologia* 31: 538A
- 8 Rustenbeck I und Lenzen S (1988) Mobilization of Ca^{2+} from intracellular stores by lysophospholipids and unsaturated fatty acids. *Naunyn-Schmiedeberg's Arch Pharmacol* 338: R33
- 9 Rustenbeck I und Lenzen S (1989) Reaction products of phospholipase A_2 as regulators of pancreatic B-cell calcium transport. *Naunyn-Schmiedeberg's Arch Pharmacol* 339: R75
- 10 Rustenbeck I und Lenzen S (1989) Reaktionsprodukte der Phospholipase A_2 als Regulatoren des Ca^{2+} Transports in B-Zellen des Pankreas. *Akt End Stoffw* 10: 124
- 11 Rustenbeck I, Trümner A und Lenzen S (1989) Quantitation of minor phospholipids from subcellular fractions of RINm5F cells. *Naunyn-Schmiedeberg's Arch Pharmacol* 340: R86
- 12 Rustenbeck I und Lenzen S (1990) Quantitation of the new antitumoral agent, hexadecylphosphocholine, in plasma. *Naunyn-Schmiedeberg's Arch Pharmacol* 341: R111
- 13 Rustenbeck I, Schulz A und Lenzen S (1990) Effects of hexadecylphosphocholine on insulin secretion from perfused mouse islets. *Diabetologia* 33: 97A
- 14 Rustenbeck I und Lenzen S (1991) Stimulation der Insulinsekretion von perfundierten Albinomausinseln durch Hexadecylphosphocholin. *Akt End Stoffw* 12: 155
- 15 Rustenbeck I, Münster W und Lenzen S (1991) Dual effect of spermine on mitochondrial calcium transport. *Naunyn-Schmiedeberg's Arch Pharmacol* 344: R38
- 16 Rustenbeck I und Münster W (1992) Polyamine modulators of mitochondrial calcium transport. *Naunyn-Schmiedeberg's Arch Pharmacol* 345: R64
- 17 Rustenbeck I, Matthies A und Lenzen S (1992) Anstieg der Phosphatidsäuremenge im Lipidmuster von glucosestimulierten Pankreasinseln. *Diabetes Stoffw* S1:94
- 18 Rustenbeck I, Eggers G und Lenzen S (1993) On the active principle of ruthenium red. *Naunyn-Schmiedeberg's Arch Pharmacol* 347: R72
- 19 Rustenbeck I, Eggers G und Lenzen S (1994) Effect of the polyamine, spermine, on the free mitochondrial matrix calcium concentration. *Naunyn-Schmiedeberg's Arch Pharmacol* 349: R34
- 20 Rustenbeck I, Eggers G, Münster W und Lenzen S (1994) Mechanism of spermine-induced enhancement of mitochondrial Ca^{2+} accumulation. *Biological Chemistry Hoppe-Seyler* 375: S86
- 21 Rustenbeck I, Löptien D, Eggers G und Lenzen S (1994) Enhancement of mitochondrial Ca^{2+} accumulation by spermine is compatible with protective effects on mitochondrial metabolism. *Naunyn-Schmiedeberg's Arch Pharmacol* 350: R16
- 22 Rustenbeck I und Lenzen S (1995) Mitochondrial phospholipase A_2 activity is not necessary for the induction of transitional Ca^{2+} release. *Naunyn-Schmiedeberg's Arch Pharmacol* 351: R89
- 23 Rustenbeck I, Kowalewski R, Herrmann C, Hasselblatt A (1995) Insulinotropic imidazoline compounds act by binding to an intracellular site. *Diabetologia* 38: A95
- 24 Rustenbeck I, Löptien D, Reiter H, Lenzen S (1995) Spermine inhibits transitional Ca^{2+} release from isolated rat liver mitochondria. *Naunyn-Schmiedeberg's Arch Pharmacol* 352: R33
- 25 Herrmann C, Ratzka P, Dickel C, Rustenbeck I und Hasselblatt A (1995) Relation between binding of imidazoline/guanidinium compounds and inhibition of K_{ATP} -channels in insulin-se-

creting cells. Naunyn-Schmiedeberg's Arch Pharmacol 352: R33

- 26 Grimmsmann T und Rustenbeck I (1996) Dissociation between increases of cytoplasmic calcium concentration and insulin release in pancreatic B-cells. Naunyn-Schmiedeberg's Arch Pharmacol. 353: R74
- 27 Herrmann C, Ratzka P, Dickel C, Rustenbeck I und Hasselblatt A (1996) Inhibitory action of imidazoline/guanidinium compounds at the K_{ATP} -channel in pancreatic B-cells in relation to their binding properties. Naunyn-Schmiedeberg's Arch Pharmacol 353: R74
- 28 Rustenbeck I, Reiter H und Lenzen S (1996) Aminoglucoside toxicity may be due to facilitation of mitochondrial membrane permeability transition. Naunyn-Schmiedeberg's Arch Pharmacol 353: R132
- 29 Herrmann C, Ratzka P, Dickel C, Rustenbeck I und Hasselblatt A (1996) Wirkung von Imidazolin/Guanidinium-Derivaten auf den K_{ATP} -Kanal der B-Zelle des Pankreas im Vergleich mit ihrem Bindungsverhalten. Diabetes Stoffw 5 (Suppl 1): 91
- 30 Rustenbeck I und Grimmsmann T (1996) Dissoziation zwischen Anstieg der cytoplasmatischen Calciumkonzentration und Auslösung der Insulinsekretion in B-Zellen des Pankreas. Diabetes Stoffw 5 (Suppl 1): 93
- 31 Herrmann C, Ratzka P, Rustenbeck I und Hasselblatt A (1996) Binding sites of imidazoline - and guanidinium compounds and functional relevance. Diabetologia 39: A121
- 32 Grimmsmann T und Rustenbeck I (1996) An energy-requiring step distal to Ca^{2+} influx in stimulus-secretion coupling in pancreatic B-cells. Diabetologia 39: A116
- 33 Herrmann C, Ratzka P, Rustenbeck, I und Hasselblatt A (1996) Imidazoline/guanidinium binding sites in insulin-secreting cells and their functional relevance. Naunyn-Schmiedeberg's Arch Pharmacol 354: R14
- 34 Grimmsmann T und Rustenbeck I (1996) An energy-requiring step distal to Ca^{2+} influx in stimulus-secretion coupling in pancreatic B-cells. Naunyn-Schmiedeberg's Arch Pharmacol 354: R14
- 35 Grimmsmann T und Rustenbeck I (1997) Diazoxide decreases mitochondrial membrane potential in intact pancreatic B-cells. Naunyn-Schmiedeberg's Arch Pharmacol 355: R82
- 36 Rustenbeck I, Leupolt L, Dickel C, Herrmann C und Hasselblatt A (1997) The different characteristics of insulin secretion by imidazolines reflect actions on membrane potassium channels. Naunyn-Schmiedeberg's Arch Pharmacol 355: R82
- 37 Krautheim A, Becker K, Rustenbeck I und Steinfelder HJ (1997) Induction of apoptosis in insulin-secreting cells by phosphatase inhibition and generation of resistant cells. Naunyn-Schmiedeberg's Arch Pharmacol 355: R82
- 38 Krautheim A, Rustenbeck I und Steinfelder HJ (1997) Inhibition of phosphatase activity induces apoptosis in insulin-secreting HIT cells. Exp Clin Endocrinol Diabetes 105: A49
- 39 Grimmsmann T und Rustenbeck I (1997) Mitochondria may form microcompartments with K_{ATP} channels in excised patches from pancreatic B-cells. Naunyn-Schmiedeberg's Arch Pharmacol 356: R26
- 40 Krautheim A, Rustenbeck I und Steinfelder HJ (1997) Characterization of resistance against okadaic acid-induced apoptosis in HIT cells. Naunyn-Schmiedeberg's Arch Pharmacol 356: R2
- 41 Rustenbeck I, Leupolt L, Grimmsmann T, Dickel C, Herrmann C und Hasselblatt A (1997) Die unterschiedliche Steigerung der Insulinsekretion durch Imidazoline entspricht den Wirkungen

dieser Substanzen auf den ATP-abhängigen K⁺-Kanal der B-Zelle. Diabetes Stoffw 6 (Suppl 3): 31

- 42 Köpp M, Rustenbeck I, Polzin C und Hasselblatt A (1998) No role for PKC activation in the stimulation of insulin secretion by imidazolines. Naunyn-Schmiedeberg's Arch Pharmacol 357: R82
- 43 Grimmsmann T, Dickel C, Winkler M und Rustenbeck I (1998) Desensitization of insulin secretion by imidazolines and other inhibitors of ATP-dependent K⁺ channels. Naunyn-Schmiedeberg's Arch Pharmacol 357: R82
- 44 Rustenbeck I, Dickel C, Herrmann C und Grimmsmann T (1998) Formation of microcompartments by mitochondria and K_{ATP} channels in inside-out patches from pancreatic B-cells. Naunyn-Schmiedeberg's Arch Pharmacol 357: R82
- 45 Krautheim A, Rustenbeck I und Steinfelder HJ (1998) Contribution of the MDR-Phenotype to okadaic acid-resistance in pancreatic HIT cells. Naunyn-Schmiedeberg's Arch Pharmacol 357: R18
- 46 Rustenbeck I und Grimmsmann T (1998) Direkte mitochondriale Wirkungen des Hemmstoffs der Insulinsekretion, Diazoxid. Diabetes Stoffw 7 (Suppl 1): 46
- 47 Rustenbeck I und Grimmsmann T (1998) Desensitization of insulin secretion by imidazolines and other inhibitors of ATP-dependent K⁺ channels. Naunyn-Schmiedeberg's Arch Pharmacol 358: R550
- 48 Rustenbeck I, Dickel C, Winkler M und Grimmsmann T (1999) Desensitization of insulin secretion by imidazolines and other insulin secretagogues. Naunyn-Schmiedeberg's Arch Pharmacol 359: R80
- 49 Rustenbeck I, Dickel C, Winkler M und Grimmsmann T (1999) Desensitisierung der Insulinsekretion durch Imidazoline und andere sekretionssteigernde Substanzen. Diabetes Stoffw 8 (Suppl 1): 76
- 50 Rustenbeck I, Dickel C, Winkler M und Grimmsmann T (1999) Desensitization of insulin secretion by inhibitors of ATP-dependent K⁺ channels. Diabetologia 42: A130
- 51 Grosse Lackmann T und Rustenbeck I (2000) Quinine blocks K_{ATP} channels by binding to the imidazoline site at the pore-forming subunit. Naunyn-Schmiedeberg's Arch Pharmacol 361: R78
- 52 Krautheim A, Jörns A, Steinfelder HJ und Rustenbeck I (2000) Effects of imidazoline insulin secretagogues on viability of pancreatic B-cells and insulin-secreting HIT cells. Naunyn-Schmiedeberg's Arch Pharmacol 361: R83
- 53 Rustenbeck I, Ahmad I, Ahamad R und Lenzen S (2000) A new class of pharmacological stimulators of insulin secretion. Naunyn-Schmiedeberg's Arch Pharmacol 361: R83
- 54 Rustenbeck I und Grosse Lackmann T (2000) Molecular mechanism of quinine-induced insulin secretion. Exp Clin Endocrinol Diabetes 108 (Suppl 1): S76
- 55 Grosse Lackmann T und Rustenbeck I (2000) Quinine and clonidine interact at imidazoline sites and block K_{ATP} channels at the pore-forming subunit. Naunyn-Schmiedeberg's Arch Pharmacol 362: R32
- 56 Rustenbeck I, Fricke K, Grosse-Lackmann T und Dickel C (2001) Antagonism of the imidazoline block of ATP-sensitive K⁺ channels by nucleotides and diazoxide. Naunyn-Schmiedeberg's Arch Pharmacol 363: R79
- 57 Ziemann C, Fricke K, Rustenbeck I, Kahl GF und Hirsch-Ernst K (2001) Does a verapamil-

sensitive p-glycoprotein-like transport mechanism participate in mitochondrial rhodamine 123-accumulation? Naunyn-Schmiedeberg's Arch Pharmacol 363: R160

- 58 Rustenbeck I, Fricke K, Grosse Lackmann T und Dickel C (2001) Antagonismus zwischen Imidazolinen und physiologischen und pharmakologischen Kaliumkanalöffnern am K_{ATP} Kanal der B-Zelle. Diabetes und Stoffwechsel 10 (Suppl 1): 28
- 59 Rustenbeck I, Krautheim A, Jörns A und Steinfelder HJ (2001) Effects of insulin secretagogues on the viability of pancreatic B-cells. Diabetologia 44: A141
- 60 Rustenbeck I, Krautheim A, Jörns A und Steinfelder HJ (2002) Induction of apoptosis and necrosis in pancreatic B-cells and insulin-secreting HIT cells by stimulators of insulin secretion. Exp Clin Endocrinol Diabetes 110: S69
- 61 Rustenbeck I, Ahmad R, Lenzen S (2002) Structure-activity relations of insulinotropic arylsulfonfylbenzimidazolones and -hydantoins. Naunyn-Schmiedeberg's Arch Pharmacol 365: R70
- 62 Rustenbeck I, Fricke K, Dickel C, Grosse Lackmann T (2002) Antagonism of imidazoline-induced K_{ATP} channel blockade by diazoxide and nucleotides. Diabetologia 45: A167
- 63 Bleck C, Rustenbeck I (2002) A re-evaluation of the putative antagonist of imidazolines at pancreatic B-cells, KU14R. Diabetologia 45: A167
- 64 Schöfl C, Remizov O, Jakubov R, Brabant G, Rustenbeck I (2002) Regulation of the cytosolic free calcium concentration and insulin secretion by palmitate in pancreatic beta-cells. Diabetologia 45: A161
- 65 Wienbergen A, Fricke K, Dickel C, Grosse-Lackmann T, Rustenbeck I (2003) Antagonism of the insulinotropic effect of imidazolines by K_{ATP} channel openers. Naunyn-Schmiedeberg's Arch Pharmacol 367: R75
- 66 Bleck C, Rustenbeck I (2003) Stimulatory and inhibitory effects of the putative antagonist of imidazolines at pancreatic B-cells, KU14R. Naunyn-Schmiedeberg's Arch Pharmacol 367: R75
- 67 Bleck C, Rustenbeck I (2003) The glucose-dependent insulinotropic effect of efaroxan and its imidazole analogue, KU14R. Diabetes Stoffw 12 (Suppl 1): 74
- 68 Wienbergen A, Dickel C, Fricke K, Grosse-Lackmann T, Rustenbeck I (2003) Antagonism of the insulinotropic effect of imidazolines by openers of K_{ATP} channels openers. Diabetes Stoffw 12 (Suppl 1): 75
- 69 Bleck C., Wienbergen A, Rustenbeck I (2003) Efaroxan, but not RX871024 is a glucose-selective insulinotropic imidazoline. Diabetes Metab 29:4S79
- 70 Bleck C, Wienbergen A, Rustenbeck I (2004) Is the imidazoline moiety necessary for the insulinotropic effect of imidazolines? Naunyn-Schmiedeberg's Arch Pharmacol 369: R72
- 71 Wienbergen A, Bleck C, Rustenbeck I (2004) Induction of oscillations of the cytosolic calcium concentration in pancreatic islets by the imidazoline efaroxan but not by RX 871024. Naunyn-Schmiedeberg's Arch Pharmacol 369: R71
- 72 Kriete C, Rustenbeck I (2004) Glucose-dependent effect of fluoroquinolones on the cytosolic calcium concentration of mouse pancreatic B-cells. Naunyn-Schmiedeberg's Arch Pharmacol 369: R72
- 73 Hatlapatka K, Elsner M, Baltrusch S, Rustenbeck I (2004) EGFP-tagging of insulin to label secretory granules in insulin-secreting cells. Diabetes und Stoffwechsel 13 (Suppl 1): 39
- 74 Bleck C, Rustenbeck I (2004) Dual effect of the imidazoline analogue, KU14R, on stimulus

- secretion-coupling in pancreatic beta-cells. *Diabetes und Stoffwechsel* 13 (Suppl 1): 53
- 75 Wienbergen A, Bleck C, Rustenbeck I (2004) Relation between glucose-dependent stimulation of insulin secretion and oscillations of the cytosolic calcium concentration in mouse pancreatic islets. *Diabetes und Stoffwechsel* 13 (Suppl 1): 123
 - 76 Bleck C, Wienbergen A, Rustenbeck I (2004) Role of the imidazoline moiety for the insulinotropic effect of imidazolines. *Diabetologia* 47: A155
 - 77 Wienbergen A, Bleck C, Rustenbeck I (2004) The imidazoline, efaroxan acts as enhancer of nutrient-induced insulin secretion. *Diabetologia* 47: A155
 - 78 Wienbergen A, Bleck C, Rustenbeck I (2005) The insulinotropic effect of efaroxan consists in an enhancement of nutrient-induced insulin secretion. *Naunyn-Schmiedeberg's Arch Pharmacol* 371: R66
 - 79 Kriete C, Rustenbeck I (2005) Insulinotropic properties of fluoroquinolones. *Naunyn-Schmiedeberg's Arch Pharmacol* 371: R66
 - 80 Hatlapatka K, Elsner M, Baltrusch S, Joerns A, Michael D, Chow R, Rustenbeck I (2005) Labelling of insulin-secretory granules by an EGFP-insulin fusion protein. *Naunyn-Schmiedeberg's Arch Pharmacol* 371: R67
 - 81 Hatlapatka K, Elsner M, Baltrusch S, Joerns A, Michael D, Chow R, Rustenbeck I (2005) Labelling of insulin-secretory granules by fluorescent insulin fusion proteins. *Diabetes und Stoffwechsel* 13 (Suppl 1): 39
 - 82 Wienbergen A, Bleck C, Rustenbeck I (2005) The glucose-selective insulinotropic effect of efaroxan. *Diabetologia* 48: A166
 - 83 Kriete C, Pflöger A, Zünkler BJ, Holzgrabe U, Rustenbeck I (2006) Different insulinotropic properties of fluoroquinolones. *Naunyn-Schmiedeberg's Arch Pharmacol* 372: R69
 - 84 Hatlapatka K, Joerns A, Chow R, Rustenbeck I (2006) Labelling of insulin-secretory granules by an EGFP-insulin fusion protein. *Naunyn-Schmiedeberg's Arch Pharmacol* 372: R70
 - 85 Hatlapatka K, Wienbergen A, Joerns A, Rustenbeck I (2007) Drug-induced desensitization of insulin secretion. *Naunyn-Schmiedeberg's Arch Pharmacol* 375: R49
 - 86 Willenborg M, Wienbergen A, Aguilar-Bryan L, Bryan J, Rustenbeck I (2007) RX871024 but not efaroxan stimulates insulin secretion by a K_{ATP} channel-independent mechanism. *Naunyn-Schmiedeberg's Arch Pharmacol* 375: R49
 - 87 Scherneck S, Nestler M, Kluge R, Neschen S, Jörns A, Rustenbeck I, Vogel H, Teichert M, Schmolz K, Schürmann A, Joost HG (2007). Transfer of the QTL *NIDD/SJL* to genetically different obese backgrounds results in different patterns of type 2-like hyperglycemia. *Naunyn-Schmiedeberg's Arch Pharmacol* 375: R48
 - 88 Hatlapatka K, Wienbergen A, Jörns A, Rustenbeck I (2007) Drug-induced desensitization of insulin secretion. *Diabetologie und Stoffwechsel* 2: S86
 - 89 Willenborg M, Wienbergen A, Aguilar-Bryan L, Bryan J, Rustenbeck I (2007) RX871024, but not efaroxan stimulates insulin secretion by a K_{ATP} -independent mechanism. *Diabetologie und Stoffwechsel* 2: S24
 - 90 Vogel H, Scherneck S, Neschen S, Vogel H, Schmolz K, Kluge R, Rustenbeck I, Schürmann A, Joost HG (2007). Die komplexe Genetik des Typ -2-Diabetes in Mausmodellen: Wirkung des diabetogenen Allels *Nidd/SJL* auf die B-Zelle bei verschiedenen genetischen Hintergründen. *Diabetologie und Stoffwechsel* 2: S13
 - 91 Hatlapatka K, Wienbergen A, Joerns A, Rustenbeck I (2007) Role of the beta cell granulation

- state in drug-induced desensitization of insulin secretion. *Diabetologia* 50 (Suppl1): S213
- 92 Willenborg M, Rustenbeck I (2008) \$. *Naunyn-Schmiedeberg's Arch Pharmacol* 375: R49
 - 93 Willenborg M, Rustenbeck I (2008) Die Glucoseabhängigkeit von Stimulatoren der Insulinsekretion - Die Rolle der Depolarisation. *Diabetologie und Stoffwechsel* 3: S53
 - 94 Hatlapatka K, Wienbergen A, Jörns A, Willenborg M, Rustenbeck I (2008) K_{ATP} channel-independent insulinotropic effect of the imidazolines: an exception to the rule? *Diabetologia* 51 (Suppl1): S197
 - 95 Willenborg M, Hatlapatka K, Rustenbeck I (2008) The role of depolarization in the initiation of insulin secretion. *Diabetologia* 51 (Suppl1): S46
 - 96 Rustenbeck I, Hatlapatka K, Willenborg M (2009) Relevance of triggering and amplifying signals for the first phase of insulin secretion. *Naunyn-Schmiedeberg's Arch Pharmacol* 379 (Suppl 1): 36
 - 97 Willenborg M, Panten U, Rustenbeck I (2009) Triggering and and amplification of insulin secretion by dimethyl α -ketoglutarate, a membrane-permeable α -ketoglutarate analogue. *Naunyn-Schmiedeberg's Arch Pharmacol* 379 (Suppl 1): 37
 - 98 Ghaly H, Kriete C, Shahin S, Pflöger A, Zünkler BJ, Holzgrabe U und Rustenbeck I (2009) The insulinotropic effects of fluoroquinolones. *Naunyn-Schmiedeberg's Arch Pharmacol* 379 (Suppl 1): 37
 - 99 Hatlapatka K, Tengholm A, Barg S, Rustenbeck I (2009) Messung der Exozytose von Insulin-Sekretgranula mittels zweier unterschiedlicher Varianten der TIRF-Mikroskopie *Diabetologie und Stoffwechsel* 4: S67
 - 100 Willenborg M, Panten U, Rustenbeck I (2009) Triggering and amplification of insulin secretion by dimethyl α -ketoglutarate, a membrane-permeable α -ketoglutarate analogue. *Diabetologie und Stoffwechsel* 4: S2
 - 101 Willenborg M, Hatlapatka K, Ghaly H, Panten U, Rustenbeck I (2009) Membrane depolarization: a fail-safe parameter to assess the triggering pathway of insulin secretion? *Diabetologia* 52 (Suppl 1) S180
 - 102 Ghaly H, Hatlapatka K, Rustenbeck I (2010) The effect of fluoroquinolones on pancreatic B-cell metabolism. *Naunyn-Schmiedeberg's Arch Pharmacol* 381(Suppl 1): 36
 - 103 Belz M, Willenborg M, Urban K, Panten U, Rustenbeck I (2010) Action potentials and insulin secretion: paradoxical effect of TEA. *Naunyn-Schmiedeberg's Arch Pharmacol* 381(Suppl 1): 37
 - 104 Willenborg M, Belz M, Ghaly H, Panten U, Rustenbeck I (2010) Das Aktionspotential und die Insulinsekretion - ein zwingender Zusammenhang? *Diabetologie und Stoffwechsel* 5: S28
 - 105 Willenborg M, Denicke S, Ghaly H, Panten U, Rustenbeck I (2010) Paradoxical membrane repolarisation during onset of insulin secretion *Diabetologia* 53 (Suppl 1) S224
 - 106 Hatlapatka K, Matz M, Baumann K, Rustenbeck I (2010) Analysis of submembrane insulin granule behaviour by TIRF microscopy during moderate and strong K^+ depolarization. *Diabetologia* 53 (Suppl 1) S226
 - 107 Belz M, Hatlapatka K, Schumacher K, Willenborg M Rustenbeck I (2011) Stimulation and inhibition of insulin secretion by potassium depolarization. *Naunyn-Schmiedeberg's Arch Pharmacol* 383 (Suppl1): 32
 - 108 Belz M Hatlapatka K, Schumacher K, Willenborg M, Rustenbeck I (2011) Stimulation und Hemmung der Insulinsekretion durch K^+ Depolarisation. *Diabetologie und Stoffwechsel* 6:

- 109 Ghaly H, Panten U, Rustenbeck I (2011) Mitochondrial function parameters during metabolic amplification of insulin secretion. *Diabetologie und Stoffwechsel* 6: S8
- 110 Hatlapatka K, Matz M, Baumann K, Rustenbeck I (2011) Bidirectional granule turnover during K^+ depolarization-induced insulin secretion. *Diabetologie und Stoffwechsel* 6: S6
- 111 Hatlapatka K, Matz M, Baumann K, Rustenbeck I (2011) Bi-directional granule turnover in the submembrane space during K^+ depolarisation-induced secretion. *Diabetologia* 54 (Suppl 1): S113
- 112 Ghaly H, Panten U, Rustenbeck I (2011) Mitochondrial function parameters during metabolic amplification of insulin secretion. *Diabetologia* 54 (Suppl 1) S198
- 113 Lehner Z, Stadlbauer K, Adorjan I, Fenzl A, Gruber D, de Cillia VAM, Frobel K, Bauer L, Rustenbeck I Luger A, Fürnsinn C (2011) Relevance of two distinct mechanisms for the antihyperglycaemic action of efaroxan in mice: antagonism to adrenergic α_2 -receptors *versus* closing of K_{ATP} -channels. *Diabetologia* 54 (Suppl 1) S242
- 114 Willenborg M., Denicke S., Ghaly H, Schumacher K, Panten U, Rustenbeck I (2012) Paradoxe Repolarisation pankreatischer Beta-Zellen während der Initiierung der Insulinsekretion. *Diabetologie und Stoffwechsel* 7: S39
- 115 Belz M, Hatlapatka K, Schumacher K, Willenborg M, Rustenbeck I (2012) Ca^{2+} -abhängige Desensibilisierung der Depolarisations-induzierten Insulinsekretion. *Diabetologie und Stoffwechsel* 7: S37
- 116 Schumacher K, Hatlapatka K, Matz M, Baumann K, Rustenbeck I (2012) Pre-exocytotic mobility of insulin granules in the submembrane space. *Diabetologie und Stoffwechsel* 7: S9
- 117 Schumacher K, Hatlapatka K, Matz M, Baumann K, and Rustenbeck I (2012) Pre-exocytotic mobility of insulin granules in the submembrane space. *Diabetologia* 55 (Suppl 1) S171
- 118 Stadlbauer K, Lehner Z, Rustenbeck I, Fenzl A, deCillia VAM, Gruber D, Luger A, Fürnsinn C (2012) Analysis of mechanisms by which pure efaroxan enantiomers increase insulin secretion from perfused mouse islets. *Diabetologia* 55 (Suppl 1) S175
- 119 Belz M, Hatlapatka K, Paufler A, Schumacher K, Willenborg M, Rustenbeck I (2012) Ca^{2+} -dependent desensitization of insulin secretion by strong potassium depolarization. *Diabetologia* 55 (Suppl 1) S176
- 120 Michael Willenborg, Michael Belz, Kirstin Schumacher, and Ingo Rustenbeck (2012) Insulin secretion induced by potassium depolarization-just a matter of Nernst equilibrium? *Diabetologia* 55 (Suppl 1) S205
- 121 M Willenborg, M Belz, A Hamada, I Rustenbeck (2013) Membrane potential-independent effect of Diazoxide on insulin secretion. *Diabetologie und Stoffwechsel* 2013; 8 - FV31 DOI: 10.1055/s-0033-1341691
- 122 K Schumacher, M Matz, K Baumann, I Rustenbeck (2013) Different effects of glucose and potassium depolarization on the granule mobility in the submembrane space of insulin-secreting MIN6 cells. *Diabetologie und Stoffwechsel* 2013; 8 - FV29 DOI: 10.1055/s-0033-1341689
- 123 Rustenbeck I, Lier-Glaubit V, Willenborg M, Engelhardt U, Jörns A (2013) Anti-obesity and anti-diabetic effect of coffee consumption in mice. *Diabetologia* 56 (Suppl 1) S159
- 124 Michael Willenborg, Michael Belz, Kirstin Schumacher, and Ingo Rustenbeck (2013) Effects of high extracellular KCl on insulin secretion beyond plasma membrane depolarization. *Diabetologia* 56 (Suppl 1) S197

- 125 Schumacher K, Matz M, Baumann K, and Rustenbeck I (2013) Different effects of glucose and potassium depolarization on the granule mobility in the submembrane space of insulin-secreting MIN6 cells. *Diabetologia* 56 (Suppl 1) S206
- 126 Stadlbauer K, Lehner Z, Stamenkovic N, Surman L, Rustenbeck I, Luger A, Fürnsinn C (2013) Evidence that two divergent mechanisms contribute to blood glucose lowering by imidazoline compounds in mice. *Diabetologia* 56 (Suppl 1) S406
- 127 Schumacher K., Willenborg M., Rustenbeck I. (2014). The Inhibitory Effect of Diazoxide on Insulin Secretion - a Re-Investigation. *Naunyn-Schmiedeberg's Arch Pharmacol* 385 (Suppl 1): \$P358
- 128 Rustenbeck I., Belz M., Willenborg M., Gorgler N., Schumacher K. (2014). Insulinotropic Effect of High Potassium Concentration beyond Plasma Membrane Depolarization. *Naunyn-Schmiedeberg's Arch Pharmacol* 385 (Suppl 1): \$P323
- 129 K Schumacher, M Matz, K Baumann, I Rustenbeck (2014) Temperature-dependent effects of glucose and potassium depolarization on granule number and mobility in the submembrane space of insulin-secreting MIN6 cells. *Diabetologie und Stoffwechsel* 9 - P183, DOI: 10.1055/s-0034-1375040
- 130 N Görgler, M Belz, M Willenborg, K Schumacher, I Rustenbeck (2014) Insulinotropic effect of high potassium concentration beyond plasma membrane depolarization. *Diabetologie und Stoffwechsel* 9 - P65 DOI: 10.1055/s-0034-1374922
- 131 Görgler N, Willenborg M, Schumacher K, Welling A, Rustenbeck I (2015) Modification of the Ca^{2+} influx pattern of the pancreatic beta cell by high extracellular potassium. *Diabetologie und Stoffwechsel* 10:S72; P256, DOI: \$
- 132 Schulze T, Morsi M, Brüning D, Schumacher K, Rustenbeck I (2015) Differences in the oxygen consumption pattern suggest that nutrient-induced insulin secretion is differentially regulated in primary mouse islets and MIN6 pseudo-islets. *Diabetologie und Stoffwechsel* 10:S72; P257, DOI: \$
- 133 Fröh E, Görgler N, and Rustenbeck I (2015) Contrasting effects of sulfonylurea and K^{+} depolarization on insulin and glucagon secretion by perfused mouse islets. *Diabetologie und Stoffwechsel* 10:S72; P254, DOI: \$
- 134 Brüning D, Schumacher K, Matz M, Baumann K, Rustenbeck I (2015) Granule mobility, fusion frequency and stimulated insulin secretion are differentially affected by insulinotropic stimuli. *Diabetologie und Stoffwechsel* 10:S73; P259, DOI: \$
- 135 D. Brüning, K. Schumacher, M. Matz, K. Baumann, I. Rustenbeck (2015). Effects of high glucose and K^{+} depolarisation on secretion and insulin granule mobility in MIN6 cells and mouse beta cells. *Diabetologia* 2015; 58(Suppl 1): S129; <https://doi.org/10.1007/s00125-015-3687-4>
- 136 N. Görgler, M. Willenborg, K. Schumacher, A. Welling, I. Rustenbeck (2015). Beta cell action potentials and Ca^{2+} currents during K^{+} depolarization. *Diabetologia* 2015; 58(Suppl 1): S208; <https://doi.org/10.1007/s00125-015-3687-4>
- 137 T. Schulze, M. Morsi, D. Brüning, K. Schumacher, and I. Rustenbeck (2015) Induction of selective unresponsiveness to glucose but not nutrient secretagogues in general by depolarization in the absence of nutrients. *Diabetologia* 2015; 58(Suppl 1): S208; <https://doi.org/10.1007/s00125-015-3687-4>
- 138 N. Seemann, A. Welling, I. Rustenbeck (2016) The inhibitor of connexin 36 hemichannels, mefloquine, affects KATP channels and L-type Ca^{2+} channels in pancreatic beta cells. *Diabetologia* 2016; 59(Suppl 1): S191; <https://doi.org/10.1007/s00125-016-4046-9>

- 139 Morsi M, Schulze T, Reckers K, Görgler N, and Rustenbeck I (2016). The metabolic amplification of insulin secretion is strongly affected by cell culture. *Diabetologie und Stoffwechsel* 11(S 01) 2016 DOI: 10.1055/s-0036-1580895.
- 140 T. Schulze, M. Morsi, D. Brüning, K. Reckers, and I. Rustenbeck (2016). Depolarization in the absence of exogenous nutrients inhibits the metabolic amplification by glucose but not KIC. *Diabetol. und Stoffwechsel* 11, FV13 (2016a).
- 141 T. Stermann, F. Menzel, C. Weidlich, K. Jeruschke, J. Weiß, A. Pujol, F. Bosch, I. Rustenbeck, A. Chadt, H. Al-Hasani (2016). The RabGAP TBC1D1 regulates glucose-stimulated insulin secretion in isolated mouse islets by modulating K⁺-ATP channel function. *Diabetologia* 2016; 59(Suppl 1): S214; <https://doi.org/10.1007/s00125-016-4046-9>
- 142 Früh E.H. and Rustenbeck, I. (2017): At low glucose arginine stimulates and sulfonylureas or K⁺ depolarization inhibit glucagon secretion by perfused mouse islets. *Diabetologie und Stoffwechsel* 12 (S 01), pp. P83*. DOI: 10.1055/s-0037-1601662.
- 143 Morsi M., Schulze T., Reckers K., Seemann N., and Rustenbeck I (2017). The effect of islet culture on the biphasic pattern of fuel-induced insulin secretion. *Diabetologie und Stoffwechsel* 2017; 12(S 01): S1-S84 DOI: 10.1055/s-0037-1601663.
- 144 Schulze T, Morsi M, and Rustenbeck I (2017) Phase-dependent differences in insulin secretion and oxygen consumption due to inhibition of protein biosynthesis by cycloheximide in mouse islets. *Diabetologie und Stoffwechsel* 2017; 12(S 01): S1-S84. DOI: 10.1055/s-0037-1601647
- 145 Brüning D, Reckers K, Drain P and Rustenbeck I (2017) Glucose but not KCl diminishes submembrane granule turnover in mouse beta cells. *Diabetologia* 2017; 60(Suppl 1): S\$;
- 146 Früh EH, Rustenbeck I (2017) At low glucose arginine stimulates and sulfonylureas or K⁺ depolarization inhibit glucagon secretion by perfused mouse islets. *Diabetologia* 2017; 60(Suppl 1): S\$;
- 147 Morsi M., Schulze T., Reckers K., and Rustenbeck I. (2017) The effect of islet culture on the biphasic pattern of fuel-induced insulin secretion. *Diabetologia* 2017; 60(Suppl 1): S\$;

Stand: 08-2017

IV Vorträge auf Einladung und Vorträge ohne publiziertes Abstract

- 1 Rustenbeck I und Lenzen S (1987) Die Bedeutung von Inositoltrisphosphat für die Regulation des Calciumtransports in B-Zellen des Pankreas. Symposium "Biochemie und Pharmakologie der Inositolphosphate" der Deutschen Gesellschaft für Pharmakologie und Toxikologie, Schloß Rauischholzhausen
- 2 Rustenbeck I und Lenzen S (1987) Die Bedeutung von Inositoltrisphosphat und Lysophosphatidylinositol für die Regulation des Calciumtransports in B-Zellen des Pankreas. 3. Inselworkshop der Deutschen Diabetesgesellschaft, Heinrich-Fabri-Institut der Universität Tübingen, Blaubeuren
- 2 Rustenbeck I, Trümner A und Lenzen S (1989) Densitometric quantification of major and minor phospholipids from subcellular fractions of pancreatic B-cells. in: Proceedings of the International Symposium on Instrumental Thin-Layer Chromatography at Brighton (RE Kaiser, ed), pp 203-206, Institute for Chromatography, Bad Dürkheim
- 3 Rustenbeck I und Lenzen S (1991) Effects of hexadecylphosphocholine on insulin release by isolated perfused mouse islets. in: Phospholipids and Signal Transmission, International Symposium and NATO Workshop, Wiesbaden
- 4 Rustenbeck I, Matthies A und Lenzen S (1992) Lipidzusammensetzung glucosestimulierter Pankreasinseln und anderer insulinproduzierender Gewebe. 4. Inselworkshop der Deutschen

- 5 Rustenbeck I, Kowalewski R, Herrmann C, Dickel C und Hasselblatt A (1995) Die Verstärkung der glucoseinduzierten Insulinsekretion durch Imidazoline ist begleitet von einem vermehrten Ca^{2+} Einstrom. 5. Inselworkshop der Deutschen Diabetesgesellschaft, Vorsymposium zur 30. Jahrestagung der Deutschen Diabetes Gesellschaft in Nürnberg.
- 6 Rustenbeck I, Leupolt L, Dickel C, Herrmann C und Hasselblatt A (1996) Insulinotropic action of imidazolines: similarities and differences. Third workshop of the Islet Research European Network (IREN). Manchester, UK
- 7 Rustenbeck I, Köpp M, Ratzka P, Leupolt L und Hasselblatt A (1998) Imidazolines and the pancreatic B-cell: actions and binding sites. Third International Symposium on Imidazoline Receptors, Bonn
- 8 Rustenbeck I, Leupolt L, Hasselblatt A und Grimmsmann T (1998) Stimulation der Insulinsekretion durch Imidazoline. 6. Inselworkshop der Deutschen Diabetesgesellschaft, Hannover
- 9 Rustenbeck I (1999) Mechanismus der insulinotropen Wirkung der Imidazoline. Seminarvortrag im Physiologisch-Pharmakologischen Kolloquium, Medizinische Universität Lübeck
- 10 Rustenbeck I (1999) Die Stimulus-Sekretionskopplung in den B-Zellen des Pankreas, physiologische und pharmakologische Aspekte. Vorlesung anlässlich der Verleihung des Ferdinand-Bertram-Preises durch die Deutsche Diabetes Gesellschaft, 34. Jahrestagung der Deutschen Diabetes-Gesellschaft in Frankfurt.
- 11 Rustenbeck I, Jörns A, Dickel C, Winkler C und Grimmsmann T (2001) Desensitization of insulin secretion by imidazolines, tolbutamide and quinine. Symposium of the EASD islet study group. Glasgow, UK
- 12 Rustenbeck I, Jörns A, Dickel C, Winkler C und Grimmsmann T (2001) Desensitisierung der Insulinsekretion durch Imidazoline, Tolbutamid und Chinin. 7. Inselworkshop der Deutschen Diabetesgesellschaft, Münster
- 13 Rustenbeck I (2003) Mechanismen der Desensitisierung der Insulinsekretion. Symposium "Regulatorische Mechanismen der Insulinsekretion" Universität Tübingen, Symposium für HPT Ammon.
- 14 Rustenbeck I (2003) Nonadrenergic imidazoline binding sites in insulin-secreting cells. Fourth International Symposium on Agmatine and Imidazoline Systems, San Diego, CA, USA
- 15 Rustenbeck I (2004) Drug-induced β -cell desensitization: experimental evidence. 5th Servier IGIS symposium, St Jean Cap Ferrat, France
- 16 Bleck C, Rustenbeck I (2004) Glucose-dependence of imidazoline-stimulated insulin secretion. 5th Servier IGIS symposium, St Jean Cap Ferrat, France
- 17 Hatlapatka K, Elsner M, Baltrusch S, Michael D, Chow RH, Rustenbeck I (2004) Labelling of insulin secretory granules by an EGFP-insulin fusion protein. Meeting of the EASD islet study group, Prien/Chiemsee, Germany
- 18 Kriete C, Rustenbeck I (2004) Fluoroquinolones increase the cytosolic calcium concentration in mouse pancreatic B-cells. World congress on antiinfective compounds, Nuremberg, Germany
- 19 Wienbergen A, Bleck C, Rustenbeck I (2005) The insulinotropic effect of efaroxan consists in an enhancement of nutrient-induced insulin secretion. 8. Inselworkshop der Deutschen Diabetesgesellschaft, Goslar

- 20 Bleck C, Wienbergen A, Rustenbeck I (2005) Role of the imidazoline moiety for the insulinotropic effect of imidazolines. 8. Inselworkshop der Deutschen Diabetesgesellschaft, Goslar
- 21 Kriete C, Pflöger A, Zünkler BJ, Holzgrabe U, Rustenbeck I (2005) Insulinotropic properties of fluoroquinolones. 8. Inselworkshop der Deutschen Diabetesgesellschaft, Goslar
- 22 Hatlapatka K, Elsner M, Baltrusch S, Joerns A, Michael D, Chow R, Rustenbeck I (2005) Labelling of insulin-secretory granules by an EGFP-insulin fusion protein. 8. Inselworkshop der Deutschen Diabetesgesellschaft, Goslar
- 23 Rustenbeck I (2005) Zimt, Chrom, pflanzliche Substanzen et al.: Aktuelle Evidenz zur blutzuckersenkenden Wirkung. 40. Jahrestagung der Deutschen Diabetes Gesellschaft, Berlin
- 24 Rustenbeck I (2005) Pathways of desensitization in the B-cell and targets to increase secretory response. Seminar der Firma Merck, Darmstadt
- 25 Rustenbeck I, Wienbergen A, Hatlapatka K, Jörns A (2006) Drug-induced desensitization of insulin secretion in normal islets. Keystone Symposium "Toward Understanding Islet Biology", Taos, New Mexico, USA
- 26 Rustenbeck I (2006) Glucose selectivity an elusive goal, drug-induced desensitization an unavoidable problem? Seminar at the Zilkha Neurogenetic Institute, Keck Medical School, University of Southern California, Los Angeles, USA
- 27 Rustenbeck I (2006) Unkonventionelle adjuvante Therapien: was geben Studien wirklich her? Interpharm-Kongreß, Frankfurt
- 28 Rustenbeck I (2006) Außenseiter-Methoden in der Diabetes-Therapie. Heidelberger Stoffwechseltage, Medizinische Universitätsklinik Heidelberg
- 29 Rustenbeck I (2006) Desensibilisierung der Insulinsekretion. Symposium Neue Aspekte der Stimulus-Sekretions-Kopplung. 41. Jahrestagung der Deutschen Diabetesgesellschaft, Leipzig
- 30 Rustenbeck I (2006) Unkonventionelle adjuvante Diabetestherapie. Fortbildungsseminar der Landesapothekerkammer Brandenburg, Potsdam
- 31 Hatlapatka K, Wienbergen A, Bleck C, Rustenbeck I (2006) Drug-induced desensitization of insulin secretion. Meeting of the EASD Islet Study Group. Helsingör/Denmark
- 32 Rustenbeck I (2006) Ist Kaffee gesund? Populäre Annahmen und epidemiologische Evidenz. Kolloquium „Kaffee im Spiegel der Wissenschaft“, Braunschweigisches Landesmuseum, Braunschweig.
- 33 Hatlapatka K, Chow R, Jörns A, Rustenbeck I (2007) Labelling of secretory granules with fluorescent insulin fusion proteins - a useful approach? Meeting of the EASD Islet Study Group. Brussels/Belgium
- 34 Willenborg M, Bleck C, Wienbergen A, Jörns A, Rustenbeck I (2007) The glucose dependency of the insulinotropic effect of imidazolines. A reinterpretation. Meeting of the EASD Islet Study Group. Brussels/Belgium
- 35 Rustenbeck I (2008) The first phase of insulin secretion: have we got the right ideas? Symposium Genetics and Pathophysiology of Type 2 Diabetes, German Institute of Nutrition, Potsdam
- 36 Willenborg M, Rustenbeck I (2008) The glucose dependence of insulin secretagogues - the role of depolarization. Symposium Genetics and Pathophysiology of Type 2 Diabetes,

German Institute of Nutrition, Potsdam

- 37 Hatlapatka K, Chow RH, Jörns A, Rustenbeck I (2008) Labelling of secretory granules with fluorescent insulin fusion proteins - a useful approach? Symposium Genetics and Pathophysiology of Type 2 Diabetes, German Institute of Nutrition, Potsdam
- 38 Rustenbeck I (2008) Pro und Contra Fixkombination. Symposium Gesundheit unter Kostendruck. Interpharm-Kongreß, Stuttgart
- 39 Rustenbeck I (2008) Imidazoline: Wirkung auf die Insulinsekretion und klinische Perspektiven. Symposium Betazell-Dysfunktion und Molekulare Aspekte der Insulinsekretion. 43. Jahrestagung der Deutschen Diabetesgesellschaft, München
- 40 Rustenbeck I (2008) Verordnung von Antidiabetika und ihre Kosten in Deutschland-Aktuelle Trends. Symposium Kosten des Diabetes in Deutschland. 43. Jahrestagung der Deutschen Diabetesgesellschaft, München
- 41 Rustenbeck I (2008) Metabolic amplification of insulin secretion. Symposium "Beta cell metabolic coupling and amplifying pathways". 44th Annual meeting of the European Association for the Study of Diabetes, Rome
- 42 Rustenbeck I (2009) Is there a role for insulinotropic antidiabetic drugs in the treatment of type 2 diabetes? 9. Inselworkshop der Deutschen Diabetesgesellschaft, Greifswald
- 43 Rustenbeck I (2009) Depolarization as trigger of insulin secretion (a reconsideration) Symposium in honour of Arnold Hasselblatt, Göttingen
- 44 Hatlapatka K, Matz M, Baumann K, Rustenbeck I (2009) Observer-independent quantitative determination of the movement of insulin secretory granules fluorescently labelled by two different granule constituents. 19th symposium of the EASD Islet Study Group. Steinschaler Dörfel/Austria
- 45 Ghaly H, Sahin S, Zünkler J, Rustenbeck I (2009) Effects of fluoroquinolones on mitochondrial energetic in mouse pancreatic islet cells. 19th symposium of the EASD Islet Study Group. Steinschaler Dörfel/Austria
- 46 Rustenbeck I, Hatlapatka K, Belz M, Schumacher K, Willenborg M (2010) Stimulation and inhibition of insulin secretion by KCl depolarization. 20th Meeting of the EASD Islet Study Group. Tällberg/Sweden
- 47 Rustenbeck I (2011) The signalling role of action potential depolarization in insulin secretion. 10th German Islet Workshop, Freiburg
- 48 Ghaly H, Panten U, Rustenbeck I (2011) Mitochondrial function parameters during metabolic amplification of insulin secretion. 10th German Islet Workshop, Freiburg
- 49 Belz M, Hatlapatka K, Schumacher K, Willenborg M, Rustenbeck I (2011) Stimulation and inhibition of insulin secretion by KCl depolarization. 10th German Islet Workshop, Freiburg
- 50 Rustenbeck I (2011) Mobilität und Exozytose von submembranären Insulinsekretgranula. Symposium „Der Blick in die beta-Zelle – neue Imagetechniken in der Insselforschung“. 46. Jahrestagung der Deutschen Diabetes Gesellschaft, Leipzig
- 51 Matz M, Schumacher K, Hatlapatka K, Baumann K, Rustenbeck I (2012) Observer-independent detection of insulin exocytosis and tracking of secretory granules by TIRF. 21st Meeting of the EASD Islet Study Group. Rostock/Germany
52. Michael Willenborg, Michael Belz, Kirstin Schumacher, Ingo Rustenbeck (2013) Effects of High Potassium on Insulin Secretion beyond Plasma Membrane Depolarization. 11th German Pancreatic Islet Cell Workshop Dresden, 15-17 April 2013

53. Kirsten Schumacher Magnus Matz, Knut Baumann and Ingo Rustenbeck (2013) Mobility of insulin granules in the submembrane space of MIN6 cells. 11th German Pancreatic Islet Cell Workshop Dresden, 15-17 April 2013
54. Ingo Rustenbeck (2014) Neue Medikamente in der Diabetestherapie. Alumnitreffen der Pharmazie, Braunschweig, Oktober 2014
54. Görgler N, Willenborg M, Schumacher K, Welling A and Rustenbeck I (2015). Effects of K⁺ depolarization on insulin secretion and beta cell Ca²⁺ influx. 12th German Pancreatic Islet Cell Workshop Bremen, 16-18 March 2015
55. Schulze T, Brüning D, Morsi M, Schumacher K and Rustenbeck I (2015) Insulin secretion, oxygen consumption and cytosolic Ca²⁺ during stimulation of mouse islets and MIN6 pseudo-islets. 12th German Islet Workshop, Bremen
56. Schumacher K, Matz M, Brüning D, Baumann K and Rustenbeck I (2015) Relation between granule mobility, fusion frequency and stimulated insulin secretion in MIN6 cells. 12th German Islet Workshop, Bremen
57. Rustenbeck I (2015) Update Nutzen/Sicherheit von Sulfonylharnstoff-Derivaten. Symposium des Ausschusses Pharmakotherapie in der 50. Jahrestagung der DDG, 14. Mai 2015, Berlin
58. Rustenbeck I (2015) The insulin granule in the submembrane space: Is there order behind disorder? Symposium "The beta cell at work". 51st Annual meeting of the European Association for the Study of Diabetes, Stockholm, Sweden
59. Rustenbeck I (2015) The mobility of insulin granules. Symposium "Regulation of beta-cell function - implication for diabetes". Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Düsseldorf
60. Rustenbeck I (2016) Update Sulfonylharnstoffe - Überwiegen Nutzen oder Risiken? 7. Ludwigshafener Diabetes-Symposium. Januar 2016 Ludwigshafen
61. Rustenbeck I (2016) Sicherheitsaspekte in der Therapie des Typ 2 Diabetes: Sulfonylharnstoffe. Diabetologische Fachgespräche - 7. Expertentreffen, Februar 2016 Hainstein/Eisenach
62. Ingo Rustenbeck, Kay Mattern, Torben Schulze, and Andreas Dietzel (2016). Microfluidics for Research on Pancreatic Islets. Gemeinsames Symposium des PVZ und der DPhG, Braunschweig, April 2016
63. Rustenbeck I (2016) Nutzen und Sicherheit der Sulfonylharnstoffe angesichts neuer Therapieoptionen des Typ 2 Diabetes. Fortbildungsveranstaltung „Diabetes und Metabolisches Syndrom“ der DPhG in Braunschweig
64. Schulze T, Mattern K, Dietzel A and Rustenbeck I (2017) Study of stimulus-secretion coupling in pancreatic islets in a microfluidic environment. Organ-on-a-Chip Europe 2017, Munich 10-11 May 2017
65. Rustenbeck I (2017) Metabolic Amplification of Insulin Secretion – How Does it Contribute to the Biphasic Kinetics? DZD-Symposium „Degeneration, regeneration and metabolism of the islets“ 52. Jahrestagung der Deutschen Diabetes Gesellschaft, Hamburg, Mai 2017